IMMP Immutep Limited

1.5
+0.02  (+1%)
Previous Close 1.48
Open 1.54
Price To Book 3.06
Market Cap 51,176,645
Shares 34,117,763
Volume 35,676
Short Ratio
Av. Daily Volume 28,020

NewsSee all news

  1. Immutep Announces Japanese Patent Grant for LAG525 Antibody

    SYDNEY, Australia, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company") is pleased to announce the grant of patent no. 6576962 entitled "Antibody molecules to

  2. Immutep Granted European Patent for Eftilagimod Alpha in Cancer

    SYDNEY, Australia, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapy treatments for cancer and

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b PFS data due 1Q 2020.
Eftilagimod Alpha - Active Immunotherapy PAClitaxel (AIPAC)
Metastatic breast cancer (MBC)
Phase 1 final data due 4Q 2019.
Eftilagimod alpha and Keytruda (TACTI-mel)
Melanoma
Phase 2 initial data due 3Q 2019.
Eftilagimod alpha and Keytruda - TACTI-002
Non-small cell lung cancer; Head and neck cancer
Phase 1 initial data due 4Q 2019.
Eftilagimod alpha - INSIGHT-004
Solid tumors

Latest News

  1. Immutep Announces Japanese Patent Grant for LAG525 Antibody

    SYDNEY, Australia, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company") is pleased to announce the grant of patent no. 6576962 entitled "Antibody molecules to

  2. Immutep Granted European Patent for Eftilagimod Alpha in Cancer

    SYDNEY, Australia, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapy treatments for cancer and